MeOmics Precision Medicine

MeOmics has developed a human neuronal cell screening platform to aid neuropsychiatric drug development. The platform uses stem cells from patient blood samples to create active neuron networks, from which it can detect signals that act as biomarkers for psychiatric disorders. Combined with patient data (clinical and genomic), the platform can predict the likelihood of drugs succeeding in clinical trials, screen for psychiatric disorders, and even develop therapeutic programs. MeOmics’ initial focus is schizophrenia.